GlaxoSmithKline and Roche announce co-development and co-promotion agreement
Basel and London, December 7, 2001 -- GlaxoSmithKline plc and Roche announced that they have signed an agreement to co-develop and co-promote ibandronate, currently in Phase III clinical development, for the treatment and prevention of Postmenopausal Osteoporosis.
Given the promising clinical trial results, Roche will be able to take full advantage of the potential of this exciting and promising medicine by collaborating with a strong development and marketing partner. Combining Roche and GSK's development, marketing and sales capabilities will provide the maximum added value for patients and prescribers.
Terms of Agreement
Under the terms of the agreement, Roche and GSK will share the future development and registration costs for the product and Roche will receive certain milestone payments from GSK. Roche will account for all sales of the product. Both companies will share profits. The companies plan to file the first drug applications with the US Food and Drug Administration and in Europe in 2002. Subject to local legal requirements, Roche and GSK plan to co-promote ibandronate in all countries, except Japan.
Topics
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.